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of chemotherapy, or in case of HSCT from the day of the 
allogeneic or autologous HSCT until discharge. During 
treatment, clinical examination and laboratory tests 
were performed every day. For bleeding prophylaxis, ir-
radiated thrombocyte concentrates collected by single 
donor apheresis were given at a thrombocyte count of 
<30 × 109/l when treated with low-molecular-weight 
heparin (LMWH), <20 × 109/l in patients with fever or 
graft-versus-host disease, or when the morning platelet 
count was <10 × 109/l. Patients with a developing throm-
bosis received LMWH as a 24-hour infusion with a tar-
get anti-FXa level of 0.2–0.4 IE/ml (measured daily), and 
LMWH infusion was immediately stopped when a bleed-
ing event scored  ≥ 3 occurred. Veno-occlusive disease 
prophylaxis with unfractionated heparin was given to 
patients treated with allogeneic HSCT after myeloabla-
tive conditioning with a dose of 5,000 units per day as a 
continuous infusion until engraftment. All protocols 
were approved by the ethics committee and all patients 
gave informed consent to their treatment and to having 
their data analyzed.
 Antidepressant drugs were categorized as SSRIs or 
non-SSRIs. The dose of antidepressants administered was 
not considered. The bleeding events were graduated us-
ing the ITP bleeding score from 0 (no hemorrhage), 1 
 Several in vivo and in vitro studies have indicated that 
selective serotonin reuptake inhibitors (SSRIs) may in-
crease the risk of bleeding [1–6]. The highest risk of he-
mostatic complications has been documented for patients 
treated concurrently with drugs interfering with plasmat-
ic hemostasis or with platelet function (e.g. oral antico-
agulation and nonsteroidal anti-inflammatory drugs) and 
for gastrointestinal bleeding as an endpoint. In contrast, 
other studies have failed to detect an association between 
SSRI treatment and a higher risk of bleeding [7–9].
 Clinically relevant bleeding due to iatrogenic throm-
bocytopenia is one of the main complications of high-
dose chemotherapy used in the treatment of leukemia 
[10]. To date, no studies have analyzed whether adminis-
tration of SSRIs is safe in terms of bleeding risk in such a 
population at a highly elevated risk for bleeding [11].
 To assess the bleeding risk, we analyzed a cohort of 
300 patients with severe iatrogenic thrombocytopenia 
undergoing high-dose chemotherapy for acute or chron-
ic leukemia (n = 100) or myeloablative conditioning che-
motherapy followed by autologous (n = 100) or alloge-
neic (n = 100) hematopoietic stem cell transplantation 
(HSCT). Data were collected from charts of consecutive 
patients treated at the Division of Hematology at Basel 
University Hospital. Data were analyzed from the start 
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(minor bleeding, e.g. few petechiae), 2 (mild bleeding 
with many petechiae and bruises, but without mucosal 
bleeding), 3 (moderate bleeding including mucosal, not 
requiring intervention), 4 (severe bleeding including in-
ternal hemorrhage, requiring intervention), and 5 (life-
threatening or fatal bleeding) [12].
 The effect of SSRI administration on bleeding risk was 
estimated using incidence rates (bleeding events per in-
hospital day undergoing or not undergoing SSRI/non-
SSRI treatment) and multivariable Cox models. Inci-
dence rates were compared using Pearson’s χ 2 test. In Cox 
models, SSRI and non-SSRI use was modeled as a time-
dependent covariable, i.e. the effect of drug administra-
tion was estimated in patients on treatment versus those 
not receiving SSRIs or non-SSRIs. Estimates were adjust-
ed for factors known to influence the bleeding risk: 
thrombocyte count, inflammation (modeled by C-reac-
tive protein), azotemia (modeled by blood urea nitrogen), 
treatment with LMWH, and the presence of graft-versus-
host disease after allogeneic HSCT [11]. All covariables 
were measured or graded daily during hospitalization 
and considered in the analysis. Non-time-dependent fac-
tors such as type of treatment (chemotherapy vs. autolo-
gous vs. allogeneic HSCT) were also included. All p values 
were 2-sided and were considered significant if <0.05. All 
statistical analyses were performed using STATA 12 
(StataCorp LP, College Station, Tex., USA).
 In our cohort, the median age was 50 years (range: 18–
80). 158 patients were treated for acute myeloid leukemia 
or myelodysplastic syndrome, 23 for acute lymphoblastic 
leukemia, 56 for multiple myeloma, 40 for lymphoprolif-
erative disorders, 9 for chronic myeloid leukemia, and 14 
for other diseases. Median duration of in-hospital treat-
ment was 24 days (range: 5–66) for a total of 7,521 patient 
days. The majority of patients (256/300, 85%) received 
one or more platelet transfusions. Of the 300 patients, 75 
(25%) were treated with an antidepressant (SSRIs n = 43, 
non-SSRIs n = 22, or both n = 10). The mean duration of 
antidepressant treatment during the inpatient period in 
this study was 16 days (range: 2–39) for SSRIs and 23 days 
(range: 3–66) for non-SSRIs. On a total of 834 patient 
days (11% of all days), patients were under treatment with 
an SSRI, and on 687 patient days (9% of all days), patients 
were under treatment with a non-SSRI. In the SSRI group, 
the administered drugs were (es)citalopram (given to 48 
patients) and sertraline (given to 5 patients). From the 
non-SSRI group, mirtazapine was given to 17 patients, 
venlaflaxine to 8 patients, trimipramine to 6 patients, and 
the remaining antidepressants once (amitriptyline, clo-
mipramine, mianserin, and trazodone).
 Bleeding events of a lower degree such as petechiae oc-
cur frequently, but without a major impact on prognosis. 
We therefore analyzed all grades of bleeding (grades 1–5), 
as well as the more clinically meaningful moderate to se-
vere bleeding events (grades 3–5). In this patient popula-
tion, a total of 187 bleeding events were recorded in 123 
patients (93 grade 1, 30 grade 2, 40 grade 3, 15 grade 4, 9 
grade 5;  fig. 1 a). The cumulative incidences of grade 1–5 
and grade 3–5 bleeding at day 50 after the start of treat-
ment were 41 ± 3% and 17 ± 2%, respectively ( fig. 1 b). 
Twenty-three bleeding events (12% of all events: 13 grade 
1, 5 grade 2, 3 grade 3, 2 grade 4, and 0 grade 5) occurred 
during SSRI treatment. Twenty bleeding events (11% of 
all events: 10 grade 1, 4 grade 2, 3 grade 3, 3 grade 4, and 
0 grade 5) occurred during non-SSRI treatment. Crude 
incidence rates per day of in-hospital days showed no in-
creased rate of bleeding of any grade in patients on treat-
ment with SSRIs or non-SSRIs, when compared to pa-
tients not undergoing such treatment ( fig. 2 ). Important-
ly, no bleeding episodes of grade 5 (life-threatening or 
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 Fig. 1.  a Distribution of severity of bleeding 
events (n = 187) occurring in 123 patients 
with thrombocytopenia after intensive 
chemotherapy. Severity is graded accord-
ing to the ITP bleeding score: 1 (minor 
bleeding, e.g. few petechiae), 2 (mild bleed-
ing with many petechiae and bruises, but 
without mucosal bleeding), 3 (moderate 
bleeding including mucosal, not requiring 
intervention), 4 (severe bleeding including 
internal hemorrhage, requiring interven-
tion), and 5 (life-threatening or fatal bleed-
ing).  b Cumulative incidences (CI) of grade 
1–5 (any grade) and grade 3–5 (moderate 
to severe) bleeding events. 
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fatal) were noted in patients under SSRI or non-SSRI 
treatment.
 In multivariable adjusted Cox regression analyses, we 
found no elevated risk for bleeding in patients undergo-
ing SSRI or non-SSRI treatment, either for bleeding of 
any grade or for bleeding of grades 3–5 [hazard ratio (HR) 
for SSRIs for bleeding grade 1–5: 0.98, 95% CI: 0.63–1.37, 
p = 0.92; HR for SSRIs for grade 3–5 bleeding: 0.48, 95% 
CI: 0.17–1.37, p = 0.17; HR for non-SSRIs for bleeding 
grade 1–5: 0.94, 95% CI: 0.64–1.40, p = 0.77; HR for non-
SSRIs for grade 3–5 bleeding: 1.11, 95% CI: 0.52–2.36, p = 
0.78]. Interaction analysis assessed if the HRs for SSRIs or 
non-SSRIs regarding bleeding risk were modulated by 
platelet counts, and found no significant interaction (p = 
0.72 for SSRIs, p = 0.88 for non-SSRIs), suggesting that 
both types of antidepressants do not increase the risk for 
bleeding even in patients with very low platelet counts. 
Similarly, no significant interaction on bleeding risk was 
found in patients treated with an SSRI or a non-SSRI and 
concurrent LMWH application (p = 0.97 and p = 0.94, 
respectively). Thirty bleeding events (16% of all events) 
occurred in the gastrointestinal tract. Similar to the over-
all risk, neither SSRI nor non-SSRI treatment significant-
ly increased the risk for gastrointestinal bleeding (HR for 
SSRIs: 0.97, 95% CI: 0.28–3.30, p  = 0.96; HR for non- 
SSRIs: 1.48, 95% CI: 0.67–3.23, p = 0.33).
 In our retrospective study, we found no significant in-
fluence of SSRI treatment on the risk of bleeding, either 
of any grade or of moderate to severe grade. Subgroup 
analyses suggested that SSRI/non-SSRI treatment also 
does not increase the risk for gastrointestinal bleeding, 
and does not increase the bleeding risk in patients with 
severe thrombocytopenia.
 In previous studies, drugs with the strongest affinity to 
the 5HT receptor, i.e. fluoxetine, paroxetine, and sertra-
line, were most frequently associated with abnormal 
bleeding [13]. Possibly, the moderate affinity for the 
transporter of most antidepressants used in this cohort 
might explain the lack of influence on bleeding risk in this 
study. Another potential mitigating factor is platelet 
transfusion, which was administered to the majority of 
patients in this study. Healthy donor platelets are rich in 
serotonin, and it was not investigated whether (and if yes 
after how much time) these transfused platelets are func-
tionally compromised when given to patients treated with 
serotonin reuptake inhibitors. 
 Apart from the effect on serotonin in platelets, other 
mechanisms responsible for increased bleeding risk in 
patients on SSRI treatment have been discussed [14]. For 
example, the increased gastrointestinal bleeding risk may 
be caused by enhanced gastric acid secretion (due to SSRI 
use) rather than the influence of thrombocyte aggrega-
tion. In our population, prophylaxis with the proton 
pump inhibitor pantoprazole was administered to all pa-
tients to reduce gastric acid production, which may have 
also mitigated effects that SSRI may have on gastrointes-
tinal bleeding risk. A limitation of this study was that the 
in-hospital exposure to antidepressant therapy was rela-
tively short, and no data were available on the duration of 
treatment in patients already treated at the start of hospi-
talization. However, while earlier studies have suggested 
that serotonin reuptake inhibition would only increase 
bleeding risk after several weeks of treatment, more re-
cent studies have shown that an increased risk for gastro-
intestinal bleeding is already apparent after 1 week of 
SSRI treatment [15]. 
 In conclusion, we could not detect an effect of SSRI or 
non-SSRI treatment on bleeding events in patients with 
severe thrombocytopenia induced by chemotherapy. 
 SSRIs [e.g. (es)citalopram] and non-SSRIs (such as mir-
tazapine) may be safely used in patients with severe 
thrombocytopenia.
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 Fig. 2. Incidence rates (per day of in-hospital treatment) of bleed-
ing events graded by the ITP bleeding score in patients not under-
going antidepressant treatment (no AD), and in patients with SSRI 
or non-SSRI treatment. 
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